Andexanet Alfa: What We Have Learned from Clinical Trials and Real-World Data Senta FrolJanja Pretnar OblakPawel Kermer Current Opinion 23 February 2024 Pages: 163 - 168
Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis Yue QiaoJian GuYing Ma Systematic Review 01 March 2024 Pages: 169 - 192
Unmet Needs in Psychodermatology: A Narrative Review Rachel E. ChristensenMohammad Jafferany Review Article 22 February 2024 Pages: 193 - 204
Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis Anastasiia D. ShkodinaMainak BardhanMykhailo Yu. Delva Review Article 29 February 2024 Pages: 205 - 224
Early Experiences with Intrathecal Administration of Amphotericin B Liposomal Formulation at a Neurosurgical Center Michael D. NailorKellie J. GoodletJ. Tyler Haller Original Research 25 January 2024 Pages: 225 - 229
Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study Lucienne Costa-Frossard FrançaVirginia Meca LallanaJosé Manuel García Domínguez Original Research Article Open access 28 February 2024 Pages: 231 - 238